NCT06213168View on ClinicalTrials.gov

Impact on Mortality of a Strategy Including Continuous Positive Airway Pressure Plus High Flow Nasal Cannula Oxygen Therapy Versus High Flow Nasal Cannula Oxygen Therapy Alone in Patients With de Novo Acute Hypoxemic Respiratory Failure: a Prospective, Randomized Controlled Trial.

NANot yet recruitingINTERVENTIONAL
Enrollment

1,084

Participants

Timeline

Start Date

September 30, 2024

Primary Completion Date

December 31, 2026

Study Completion Date

March 31, 2027

Conditions
De Novo Hypoxemic Acute Respiratory Failure (hARF)
Interventions
OTHER

HFNC

Patients assigned to the control group will be continuously treated by HFNC. HFNC will be initiated within one hour following randomization

OTHER

CPAP and HFNC

Patients assigned to the intervention group will receive high flow nasal oxygen plus CPAP sessions

All Listed Sponsors
lead

Assistance Publique - Hôpitaux de Paris

OTHER

NCT06213168 - Impact on Mortality of a Strategy Including Continuous Positive Airway Pressure Plus High Flow Nasal Cannula Oxygen Therapy Versus High Flow Nasal Cannula Oxygen Therapy Alone in Patients With de Novo Acute Hypoxemic Respiratory Failure: a Prospective, Randomized Controlled Trial. | Biotech Hunter | Biotech Hunter